Assembly Bio reports FY 2023 net loss of $61.2M; cash of $130.2M; outlines 2024 milestones

ASSEMBLY BIOSCIENCES, INC.

Cash, equivalents and marketable securities $130.2M as of Dec 31, 2023, up from $91.6M at end of 2022; funded into H2 2025.
Revenue from collaborations $7.2M in FY 2023 (vs $0 in 2022), primarily from Gilead partnership.
R&D expenses $48.9M (down from $70.0M); net loss $61.2M ($13.38/share) vs $93.1M ($23.08) in 2022.
Phase 1a interim data for HSV drug ABI-5366 expected Q3 2024; Phase 1b data for HBV drug ABI-4334 by end of 2024.
Entered long-term partnership with Gilead and appointed Anuj Gaggar as CMO.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ASSEMBLY BIOSCIENCES, INC. reported the quarter and year ended December 31, 2023 results: revenue $7.2 million, net income $61.2 million, EPS $13.38 per basic and diluted share.

Period: the quarter and year ended December 31, 2023
Revenue: $7.2 million
Net income: $61.2 million
EPS: $13.38 per basic and diluted share
Result: reported results

Exact text from the filing

as of the year ended December 31, 2022. The company’s cash position is projected to fund operations into the second half of 2025. • Revenues from collaborative research were $7.2 million for the year ended December 31, 2023. There was no revenue recognized for the same period in 2022. Revenue for the year ended December 31, 2023, consists of $4.4 million

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

ASSEMBLY BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-038044

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.